Recordings

How could evidence-based psychedelic therapies help address war-related mental health challenges in Ukraine, particularly PTSD among veterans? This was the main question of the European Parliament event held on 6 May, which Drugreporter captured on video in its entirety.

Maryam took part in a Compass Pathways phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression. The testimonial was made during the MEP Action Group for the Medical Use of Psychedelics meeting "Innovating Mental Health in the EU Pharma Legislation.

There is a growing belief that research around the potential of psychedelics is finally making key policymakers within the European Parliament stand up and take notice. With organisations like PAREA now facilitating meaningful conversations which could lead to a shift in perception, how could the EU take a central role in driving psychedelic healthcare to become a reality across Europe? PSYCH Symposium's panel of change-makers and MEPs discussed how far the needle has moved and which actions are needed to bring about an evolution in approach.

On 6th December, PAREA organized our first policy meeting in the European Parliament, looking at the basic ingredients of psychedelic novel treatments captured in the event’s title: “Psychedelic-assisted therapies in the treatment of brain disorders”.

To further shape the discussions on the responsible and safe rollout of those treatments in the future, at the event, PAREA launched “An appeal to the European Union institutions and Member States”. You can learn more details here: https://parea.eu/eu-parliament-appeal

On 23 June 2022, the Psychedelic Access and Research European Alliance - PAREA, was officially launched at a virtual event: Preparing Europe for Novel Psychedelic-Assisted Therapies. Keynote Address was delivered by Dr Thomas Insel, former Director of the US National Institute of Mental Health (2002 - 2015).